Lyon-based biotech company Meddenovo, which uses AI technologies and molecular modeling to design unique drug candidates, has raised €1 million from ACT Venture Partners to further develop its AI-powered platforms for therapeutic solutions.
- Founded in 2021 by Antoine Marion and Ilke Ugur Marion, Meddenovo develops an AI-driven drug discovery platform for peptide-based medicines and metal chelators to enhance efficiency and success rates in drug development processes.
- Meddenovo offers specialized computational solutions for predicting drug resistance, analyzing biochemical reaction mechanisms, and evaluating metal affinity. By prioritizing precision and reliability, the company enhances drug discovery efforts and provides scientists with advanced AI tools to support their research.
Details of the deal
- The pre-seed funding round was supported by ACT Venture Partners, an Amsterdam-based venture capital firm that invests in early-stage tech startups. To date, the firm has backed 21 startups, made 47 investments, and exited 4 companies, including Inofab Health, Flank Esports, and BioCapSOL.
- The capital raised will allow Meddenovo to enhance its AI-driven capabilities, transition to a SaaS model, and expand its partnerships and customer base.
